Opioid Treatment Programs Drug Enforcement Administration James Jim Arnold Chief Policy Unit Office of Diversion Control D E A Headquarters November 2014 1 OD Mission Statement The Office of Diversion Controls Mission is to ID: 268520
Download Presentation The PPT/PDF document "“Medication Units”" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
“Medication Units” (Opioid Treatment Programs)
Drug Enforcement Administration
James “Jim” ArnoldChief, Policy Unit Office of Diversion ControlD E A HeadquartersNovember 2014
1Slide2
OD: Mission StatementThe Office of Diversion Control’s Mission is to Prevent, Detect
, and Investigate the Diversion of Pharmaceutical Controlled Substances and Listed Chemicals
from Legitimate Channels While Ensuring an Adequate and Uninterrupted Supply of Pharmaceutical Controlled Substances to Meet Legitimate Medical
, Commercial, and Scientific Needs.
2Slide3
AuthorityLaw Controlled Substance Act United States Code: Title 21 Food & Drugs (Sections 801-971)
Regulations Code of Federal Regulations Title 21 Food & Drugs (Parts 1300-1321)
PolicyWritten Memorandums, LettersPublications (Federal Register)
3Slide4
Title 42: 8.2 DefinitionsMedication unit
means a facility established as part of, but geographically separate from, an opioid treatment program from which licensed private practitioners or community pharmacists
dispense or administer an opioid agonist treatment medication or collect samples for drug testing or analysis.
4Slide5
Law: 21 USC 822 (a) (1) Persons Required to Register:(1) Every person who manufactures or
distributes any controlled substance or list I chemical, or who proposes to engage in the manufacture or distribution of any controlled substance or list I chemical, shall obtain annually a registration issued by the Attorney General in accordance with the rules and regulations promulgated by him
5Slide6
Law: 21 USC 822 (a) (2) Persons Required to Register:“Every person who dispenses, or who proposes to dispense,
any controlled substance, shall
obtain from the Attorney General a registration issued in accordance with the rules and regulations promulgated by him.
6Slide7
Law: 21 USC 822 (e) Separate registration
A separate registration shall be required at each principal place of business or professional practice where the applicant manufactures, distributes, or dispenses controlled substances
or list I chemicals.
7Slide8
Law: 21 USC 827 (a)(1),(2)Inventories: Initial Inventory:
-When registrant first engages in manufacture/distribution/dispensing
Biennial Inventory: -Every second year thereafter -Complete and Accurate Record of all Stocks on Hand
8Slide9
Law: 21 USC 827 (a)(3)“…every registrant … manufacturing, distributing, or dispensing a controlled substance…shall maintain, on a current basis, a complete and accurate
record of each substance manufactured, received
, sold, delivered, or otherwise disposed of …”
9Slide10
Law: 21 USC 827 (b)Availability of Records: -Contain Information and Be in a Form as Required by Regulation
. -Be in a Form That is Readily Retrievable. -Be Kept and Available for
Two Years.
10Slide11
Federal Law & Regulation
11
Although medication units are exempt from NTP (OTP) licensing requirements by CSAT, under Federal law they must have a separate
D E A (NTP) registration: 21 USC 822 (e). Medication units are required to maintain separate inventories, records, reports, and security in accordance with D E A regulations.Slide12
Federal LawMedication units are another method of expanding narcotic treatment. D E A regulations require that currently approved and available controlled substance medications (e.g. Methadone, Buprenorphine, BCP’s) be dispensed directly to the patient by a practitioner registered with D E A as a “narcotic treatment program.” Prescribing remains prohibited under an NTP Registration: 21 CFR 1306.07 (a).
12Slide13
Law: 21 USC 822 (f) The Attorney General is authorized to inspect the establishment of a registrant or applicant for registration in accordance with the rules and regulations promulgated by him.
13Slide14
Record Requirements (1 of 2)
Inventories21 CFR 1304.11
D E A 222 Order Forms21 CFR 1305Dispensing Records21 CFR 1304.24Reports of Theft or Loss21 CFR 1301.74(c) – D E A Form 106Drug Destruction Records21 CFR 1304.21(e) – D E A Form-41
14Slide15
Record Requirements (2 of 2)
Name of substance
Strength of substanceDosage formDate dispensed Dispenser’s initialsAdequate identification of patient Amount consumed (patient)Amount & dosage form taken home by patient
15Slide16
SecuritySafes, Steel Cabinets, or Vaults
21 CFR 1301.72 (a), (b)Alarm Systems21 CFR 1301.72 (a)
Accessibility of Controlled Substances21 CFR 1301.72 (d)21 CFR 1301.74 (h)21 CFR 1301.74 (i)21 CFR 1301.74 (j)D E A Discretion (Security)21 CFR 1301.74 (l)
16Slide17
D E A DiscretionD E A may exercise discretion regarding the degree of security required in narcotic treatment programs based on such factors as the location of a program, the number of patients enrolled in a program and the number of physicians, staff members and security guards. Similarly, such factors will be taken into consideration when evaluating existing security or requiring new security at a narcotic treatment program.
17Slide18
Office of Diversion Control
http://www.DEAdiversion.usdoj.gov/
18Slide19
Publications & Manuals
19Slide20
Any Questions Concerning D E A’s Presentation Today Can Be Sent to D E A at
ODL@DEA.usdoj.gov
20Slide21
21
Contact Information:
Drug Enforcement Administration 8701 Morrissette Drive Springfield, Virginia 22317 Attn: James Arnold, Chief/Policy/ODLP 202-353-1414 (Office) 202-353-1263 (Fax) James.A.Arnold@usdoj.gov